Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin + Pembrolizumab vs Pembrolizumab in HNSCC
NCT04969861Phase 3Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of bempegaldesleukin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Nektar Therapeutics. Primary endpoints: Overall Survival at 2 years and Objective Response Rate at 2 years. Started Mar 2022; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04969861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969861.